Funded Projects
Explore our currently funded projects. You may search with all three fields, then focus your results by applying any of the dropdown filters. After customizing your search, you may download results and even save your specific search for later.
Project # | Project Title | Research Focus Area | Research Program | Administering IC Sort descending | Institution(s) | Investigator(s) | Location(s) | Year Awarded |
---|---|---|---|---|---|---|---|---|
3U19TW007401-14S1
Show Summary |
EXPLORATION, CONSERVATION, & DEVELOPMENT OF MARINE BIODIVERSITY IN FIJI AND THE SOLOMON ISLANDS | Preclinical and Translational Research in Pain Management | FIC | GEORGIA INSTITUTE OF TECHNOLOGY | HAY, MARK E | ATLANTA, GA | 2018 | |
NOFO Title: Limited Competition: International Cooperative Biodiversity Groups (U19)
NOFO Number: RFA-TW-13-001 Summary: This International Cooperative Biodiversity Group application aims to discover and develop small molecule drug leads from cultured marine microbes and diverse coral reef organisms collected from Fiji and the Solomon Islands. Drug discovery efforts will focus on four major disease areas of relevance to the United States and low- and middle-income countries: infectious disease, including tuberculosis and drug-resistant pathogens; neglected tropical diseases, including hookworms and roundworms; cancer; and neurodegenerative and central nervous system disorders. Screening in these therapeutic areas will be performed in collaboration with two major pharmaceutical companies, two highly respected academic groups, and various testing centers and government resources that are available to facilitate drug discovery and development. The acquisition of source material for this program will be linked to biotic surveys, informed by ecological investigations addressing the chemical mediation of biotic interactions, and enriched using ecology-based strategies designed to maximize secondary metabolite production and detection. |
||||||||
3U19TW009872-05S1
Show Summary |
NOVEL THERAPEUTIC AGENTS FROM THE BACTERIAL SYMBIONTS OF BRAZILIAN INVERTEBRATES | Preclinical and Translational Research in Pain Management | FIC | HARVARD MEDICAL SCHOOL | CLARDY, JON; PUPO, MONICA T | Boston, MA | 2018 | |
NOFO Title: Limited Competition: International Cooperative Biodiversity Groups (U19)
NOFO Number: RFA-TW-13-001 Summary: An International Cooperative Biodiversity Group with an interdisciplinary leadership team of physicians, pharmacologists, evolutionary biologists, and chemists will discover and develop therapeutic agents produced by Brazilian symbiotic bacteria. The team will target three therapeutic areas: 1) infectious fungal pathogens, 2) Chagas disease and leishmaniasis, and 3) cancers of the blood. All three areas represent major threats to human health that need to be addressed with new therapeutic agents. Internationally, invasive fungal diseases kill more people than malaria or TB, while Chagas disease imposes a special burden on Brazil, killing as many Brazilians as TB. Leishmaniasis has now passed Chagas disease in the Brazilian population. Despite major improvements in cancer chemotherapy, cancer is projected to result in 8 million deaths internationally this year (13% of all deaths, WHO) and an estimated 13 million per year by 2030. |
||||||||
3U19TW008163-10S1
Show Summary |
DIVERSE DRUG LEAD COMPOUNDS FROM BACTERIAL SYMBIONTS IN PHILIPPINE MOLLUSKS | Preclinical and Translational Research in Pain Management | FIC | UNIVERSITY OF UTAH | HAYGOOD, MARGO GENEVIEVE | Salt Lake City, UT | 2018 | |
NOFO Title: Limited Competition: International Cooperative Biodiversity Groups (U19)
NOFO Number: RFA-TW-13-001 Summary: The Philippine Mollusk Symbiont International Cooperative Biodiversity Group harnesses the vast biodiversity of the Philippines to discover new drugs to treat bacterial infections, parasitic infections, pain, and other neurological conditions and cancer, all of which are serious health problems in both the Philippines and the United States. The Republic of the Philippines represents a unique nexus of exceptional biodiversity, dense human population with pressing societal needs, consequent urgent need for conservation, and government commitment to education and technology to harness national human and natural resources for a sustainable future. Mollusks are one of the most diverse groups of marine animals, and their associated bacteria represent an unexplored trove of chemical diversity. Researchers will use an increasing understanding of the interactions between mollusk symbionts and their hosts to discover the most novel and useful molecules. The project will document and describe Philippine mollusk biodiversity and support training and infrastructure that provide the foundation for conservation of Philippine biodiversity. |
||||||||
3UG3TR002151-01S1
Show Summary |
INTEGRATED MICROPHYSIOLOGICAL SYSTEM OF CEREBRAL ORGANOID AND BLOOD VESSEL FOR DISEASE MODELING AND NEUROPSYCHIATRIC DRUG SCREENING | Preclinical and Translational Research in Pain Management | NCATS | COLUMBIA UNIVERSITY HEALTH SCIENCES | LEONG, KAM W | NEW YORK, NY | 2018 | |
NOFO Title: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
NOFO Number: PA-18-591 Summary: The clinical utility of opioids for pain treatment is limited by its risk for developing opioid usage disorders (OUD). These untoward effects impose a severe burden on society and present difficult therapeutic challenges for clinicians. We propose to extend our cerebral organoid MPS to facilitate the investigation of neuronal response to opioids and identify cellular and molecular signatures in patients vulnerable to OUD. We have assembled a team with complementary expertise in clinical characterization of OUD, cerebral organoid MPS modeling, single cell RNA-seq technology, and functional characterization of neurons in a mesolimbic reward system to test the hypothesis that midbrain MPS is a clinically relevant pre-clinical model for study of opioid usage disorder. |
||||||||
1UG3TR003081-01
Show Summary |
Multi-organ human-on-a-chip system to address overdose and acute and chronic efficacy and off-target toxicity | Preclinical and Translational Research in Pain Management | Translational Research to Advance Testing of Novel Drugs and Human Cell-Based Screening Platforms to Treat Pain and Opioid Use Disorder | NCATS | UNIVERSITY OF CENTRAL FLORIDA | HICKMAN, JAMES J (contact); SHULER, MICHAEL L | Orlando, FL | 2019 |
NOFO Title: HEAL Initiative: Tissue Chips to Model Nociception, Addiction, and Overdose (UG3/UH3 Clinical Trial Not Allowed)
NOFO Number: RFA-TR-19-003 Summary: This project will build overdose models for fentanyl, methadone, codeine, and morphine in a multi-organ system and evaluate the acute and repeat dose, or chronic effects, of overdose treatments as well as off-target toxicity. Researchers developed a system using human cells in a pumpless multi-organ platform that allows continuous recirculation of a blood surrogate for up to 28 days. They will develop two overdose models for male and female phenotypes based on pre-B?tzinger Complex neurons and will integrate functional immune components that enable organ-specific or systemic monocyte actuation. Models for cardiomyopathy and infection will be utilized. Researchers will establish a pharmacokinetic/pharmacodynamic model of overdose and treatment to enable prediction for a range of variables. We will use a serum-free medium with microelectrode arrays and cantilever systems integrated on chip that allow noninvasive electronic and mechanical readouts of organ function. |
||||||||
3R42TR001270-03S1
Show Summary |
PERIPHERAL NERVE-ON-A-CHIP FOR PREDICTIVE PRECLINICAL PHARMACEUTICAL TESTING | Cross-Cutting Research | Small Business Programs | NCATS | AXOSIM, INC. | CURLEY, JABE L; MOORE, MICHAEL J | NEW ORLEANS, LA | 2018 |
NOFO Title: PHS 2016-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
NOFO Number: PA-16-303 Summary: The ability to de-risk lead compounds during pre-clinical development with advanced “organoid-on-a-chip” technologies shows promise. Development of microphysiological models of the peripheral nervous system is lagging. The technology described herein allows for 3D growth of high-density axonal fiber tracts, resembling peripheral nerve anatomy. The use of structural and functional analyses should mean drug-induced neural toxicity will manifest in these measurements in ways that mimic clinical neuropathology. The goals of this proposal are to establish our human model using relevant physiological measurements in tissues fabricated from human iPS cells and to validate the model system with a library of compounds, comparing against conventional cell culture models. Validating the peripheral nerve model system with drugs known to induce toxicity via a range of mechanisms will demonstrate the ability of the system to predict various classifications of neuropathy, yielding a high-content assay far more informative than traditional in vitro systems. |
||||||||
1UG3TR003150-01
Show Summary |
Human Microphysiological Model of Afferent Nociceptive Signaling | Preclinical and Translational Research in Pain Management | Translational Research to Advance Testing of Novel Drugs and Human Cell-Based Screening Platforms to Treat Pain and Opioid Use Disorder | NCATS | TULANE UNIVERSITY OF LOUISIANA | MOORE, MICHAEL J (contact); ASHTON, RANDOLPH S; RAJARAMAN, SWAMINATHAN | New Orleans, LA | 2019 |
NOFO Title: HEAL Initiative: Tissue Chips to Model Nociception, Addiction, and Overdose (UG3/UH3 Clinical Trial Not Allowed)
NOFO Number: RFA-TR-19-003 Summary: This project will develop a human cell-based model of the afferent pain pathway in the dorsal horn of the spinal cord. The research team’s approach utilizes novel human pluripotent stem cell (hPSC)-derived phenotypes in a model that combines 3D organoid culture with microfabricated systems on an integrated, three-dimensional (3D) microelectrode array. Researchers will establish the feasibility of a physiologically relevant, human 3D model of the afferent pain pathway that will be useful for evaluation of candidate analgesic drugs. They will then improve the physiological relevance of the system by promoting neural network maturation before demonstrating the system’s utility in modeling adverse effects of opioids and screening compounds to validate the model. Completion of the study objective will establish novel protocols for deriving dorsal horn neurons from hPSCs and create the first human microphysiological model of the spinal cord dorsal horn afferent sensory pathway. |
||||||||
1UG3TR003090-01
Show Summary |
Joint Pain on a Chip: Mechanistic Analysis, Therapeutic Targets, and an Empirical Strategy for Personalized Pain Management | Preclinical and Translational Research in Pain Management | Translational Research to Advance Testing of Novel Drugs and Human Cell-Based Screening Platforms to Treat Pain and Opioid Use Disorder | NCATS | UNIVERSITY OF PITTSBURGH AT PITTSBURGH | GOLD, MICHAEL S (contact); LIN, HANG | Pittsburgh, PA | 2019 |
NOFO Title: HEAL Initiative: Tissue Chips to Model Nociception, Addiction, and Overdose (UG3/UH3 Clinical Trial Not Allowed)
NOFO Number: RFA-TR-19-003 Summary: The research team developed an in vitro multi-component joint on a chip (microJoint), in which engineered osteochondral complexes, synovium, and adipose tissues were integrated. This study will introduce sensory innervation into the microJoint and a neuron-containing microfluidic ally will be developed to innervate the microJoint. The osteoarthritis (OA) model will be created in the Neu-microJoint system. The research team will assess activation and/or sensitization of nociceptive afferents with electrophysiology, as well as neurite outgrowth. They will mechanically insult the Neu-microJoint and assess the emergence of “pain” in response to prolonged mechanical stress. Researchers will assess the impact of drugs used clinically for management of OA on OA models and will then use “omic” approaches to identify new biomarkers and therapeutic targets. Researchers will assess the impact of opioids—which they hypothesize will increase the rate of joint degeneration and potentiate the release of pain-producing mediators—on neural activity in the presence and absence of joint injury, as well as the integrity of all joint elements. |
||||||||
1UG3TR003148-01
Show Summary |
Multi-organ-on-chip device for modeling opioid reinforcement and withdrawal, and the negative affective component of pain: a therapeutic screening tool. | Preclinical and Translational Research in Pain Management | Translational Research to Advance Testing of Novel Drugs and Human Cell-Based Screening Platforms to Treat Pain and Opioid Use Disorder | NCATS | UNIVERSITY OF CALIFORNIA LOS ANGELES | MAIDMENT, NIGEL T (contact); ASHAMMAKHI, NUREDDIN ; SEIDLITS, STEPHANIE KRISTIN; SVENDSEN, CLIVE NIELS | Los Angeles, CA | 2019 |
NOFO Title: HEAL Initiative: Tissue Chips to Model Nociception, Addiction, and Overdose (UG3/UH3 Clinical Trial Not Allowed)
NOFO Number: RFA-TR-19-003 Summary: Researchers will develop multi-organ, microphysiological systems (MPSs) based on human induced pluripotent stem cell-derived midbrain-fated dopamine (DA)/gamma-aminobutyric acid neurons on a three-dimensional platform that incorporates microglia, blood–brain barrier (BBB), and liver metabolism. RNA sequencing and metabolomics analyses will complement the primary DA release measure to identify novel mechanisms contributing to chronic opioid-induced plasticity in DA responsiveness. The chronic pain-relevant aspect of the model will be realized by examination of aversive kappa-mediated opioid effects on DA transmission in addition to commonly abused mu opioid receptor agonists, and by incorporation of inflammatory-mediating microglia. Incorporation of BBB and liver metabolism modules into the microphysiologic system platform will permit screening of drugs. Throughput will be increased by integration of online sensors for online detection of DA and other analytes. Researchers will use a curated set of 100 chemical genomics probes. |
||||||||
3U24TR001597-04S1
Show Summary |
TIN Supplement | Clinical Research in Pain Management | Pain Management Effectiveness Research Network (ERN) | NCATS | University of Utah | Dean, Jonathan Michael | Salt Lake City, UT | 2019 |
NOFO Title: CTSA Network - Trial Innovation Centers (TICs) (U24)
NOFO Number: RFA-TR-15-002 |
||||||||
1DP2TR004354-01
Show Summary |
Scale Up Single-Cell Technologies to Map Pain-Associated Genes and Cells Across the Lifespan | Cross-Cutting Research | Training the Next Generation of Researchers in HEAL | NCATS | Massachusetts General Hospital | SHU, JIAN | Boston, MA | 2022 |
NOFO Title: Emergency Awards: HEAL Initiative- New Innovator Award (DP2 Clinical Trial Not Allowed)
NOFO Number: RFA-tr-22-013 Summary: Current treatments for chronic pain, including opioids, are not effective for many individuals. Much remains unknown about genes, circuits, and cells that contribute to chronic pain, including how chronic pain changes across the lifespan in certain populations, including infants, children, older people, and pregnant women. This project will develop technology to map the genes, circuits, and cells associated with pain across ages, sexes, and during pregnancy. The technologies will guide the search for new biomarkers for chronic pain diagnosis and treatments. |
||||||||
3U24TR001608-04S1
Show Summary |
TIN Supplement | Clinical Research in Pain Management | Pain Management Effectiveness Research Network (ERN) | NCATS | Duke University | Benjamin, Daniel K. | Durham, NC | 2019 |
NOFO Title: CTSA Network - Trial Innovation Centers (TICs) (U24)
NOFO Number: RFA-TR-15-002 |
||||||||
3U24TR001609-04S1
Show Summary |
TIN Supplement | Clinical Research in Pain Management | Pain Management Effectiveness Research Network (ERN) | NCATS | Johns Hopkins University | Hanley, Daniel | Baltimore, MD | 2019 |
NOFO Title: CTSA Network - Trial Innovation Centers (TICs) (U24)
NOFO Number: RFA-TR-15-002 |
||||||||
3U24TR001579-04S1
Show Summary |
TIN Supplement | Clinical Research in Pain Management | Pain Management Effectiveness Research Network (ERN) | NCATS | Vanderbilt University | Harris, Paul A | Nashville, TN | 2019 |
NOFO Title: Clinical and Translational Science Award (CTSA) Network Recruitment Innovation Centers (RICs)(U24)
NOFO Number: RFA-TR-15-004 |
||||||||
3UG3TR003149-02S1
Show Summary |
Supplement to hiPSC-based DRG Tissue Mimics on Multi-well Microelectrode Arrays as a Tissue Chip Model of Acute and Chronic Nociception | Preclinical and Translational Research in Pain Management | Discovery and Validation of Novel Targets for Safe and Effective Treatment of Pain | NCATS | UNIVERSITY OF TEXAS DALLAS | BLACK, BRYAN JAMES | Dallas, TX | 2020 |
NOFO Title: Notice of Special Interest for HEAL Initiative: Request for Administrative Supplements to Existing Grants for Identification and Validation of New Pain and Opioid Use Disorder Targets within the Understudied Druggable Genome
NOFO Number: NOT-TR-20-008 Summary: This study aims to determine whether a subset of understudied genes that are expressed in human and mouse dorsal root ganglia (DRG) tissues (critical for relaying the sensation of pain from the body to the central nervous system), are also expressed in human induced pluripotent stem cell DRG mimetics. The study will also determine if these genes are involved in neuronal excitability changes under inflammatory conditions and compare these responses to those of primary DRG neurons. Third and finally, the study will optimize genetic depletion of target genes enabling future fundamental and preclinical research studies. |
||||||||
3UG1CA189824-07S2
Show Summary |
Wake Forest NCORP Research Base | Clinical Research in Pain Management | Pain Management Effectiveness Research Network (ERN) | NCATS | WAKE FOREST UNIVERSITY HEALTH SCIENCES | LESSER, GLENN J | Winston-Salem, NC | 2020 |
NOFO Title: Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for Administrative Supplements to Promote Training in Clinical Research on Pain (Admin Supp ? Clinical Trial Not Allowed)
NOFO Number: NOT-NS-20-044 Summary: Pain is one of the most common symptoms in cancer patients and one least likely to be adequately treated. It is particularly common in advanced cancer, affecting an estimated 64% of patients with advanced disease. Pain treatment guidelines state patients should have access to behavioral pain interventions that educate them about pain and teach them skills for managing it. The parent grant will evaluate the effectiveness of an evidence based pain management intervention called ?Pain Coping Skills Training? in a web based format for patients with advanced cancer. This supplement will provide support for a training opportunity that aligns with the goals of the parent grant and includes community outreach and engaging underserved populations in clinical research. |
||||||||
1UG3TR003149-01
Show Summary |
hiPSC-based DRG Tissue Mimics on Multi-well Microelectrode Arrays as a Tissue Chip Model of Acute and Chronic Nociception | Preclinical and Translational Research in Pain Management | Translational Research to Advance Testing of Novel Drugs and Human Cell-Based Screening Platforms to Treat Pain and Opioid Use Disorder | NCATS | UNIVERSITY OF TEXAS DALLAS | BLACK, BRYAN JAMES | Dallas, TX | 2019 |
NOFO Title: HEAL Initiative: Tissue Chips to Model Nociception, Addiction, and Overdose (UG3/UH3 Clinical Trial Not Allowed)
NOFO Number: RFA-TR-19-003 Summary: Researchers will develop an innovative three-dimensional (3D) model of acute and chronic nociception using human induced pluripotent stem cell (hiPSC) sensory neurons and satellite glial cell surrogates. They will develop a tissue chip for modeling acute and chronic nociception based on 3D hiPSC-based dorsal root ganglion tissue mimics and a high-content, moderate-throughput microelectrode array. Researchers will demonstrate stable spontaneous and noxious stimulus-evoked behavior in response to thermal, chemical, and electrical stimulation challenges. They aim to demonstrate sensitivity to translational control via ligand receptor interactions between neuronal and non-neuronal cell types. They also will demonstrate the quantitative efficiency and preclinical efficacy of our system by detecting known ligand-based modulators of translational control and voltage-gated ion channel antagonists in a sensitized model of chronic nociception. Researchers will leverage the high-throughput nature of our tissue chip model to screen Food and Drug Administration–approved bioactive compounds. |
||||||||
3R44TR001326-03S1
Show Summary |
Automation and validation of human on a chip systems for drug discovery | Cross-Cutting Research | Small Business Programs | NCATS | HESPEROS, LLC | SHULER, MICHAEL L; HICKMAN, JAMES J | Orlando, FL | 2019 |
NOFO Title: PHS 2017-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
NOFO Number: PA-17-302 Summary: Hesperos uses microphysiological systems in combination with functional readouts to establish systems capable of analysis of chemicals and drug candidates for toxicity and efficacy during pre-clinical testing, with initial emphasis on predictive toxicity. The team constructed physiological systems that represent cardiac, muscle and liver function, and demonstrated a multi-organ functional cardiac/liver module for toxicity studies as well as metabolic activity evaluations. In addition, the team demonstrated multi-organ toxicity in a 4-organ system composed of neuronal, cardiac, liver and muscle components. While much is known about the cells and neural circuitry regulating pain modulation there is limited knowledge regarding the precise mechanism by which peripheral and spinal level antinociceptive drugs function, and no available human-based model reproducing this part of the pain pathway. The ascending pain modulatory pathways provide a well characterized neural architecture for investigating pain regulatory physiology. In this project, the research team propose a human-on-a-chip neuron tri-culture system composed of nociceptive neurons, GABAergic interneurons and glutamatergic dorsal projection neurons (DPN) integrated with a MEMS construct. Using this model, investigators will interrogate pain signaling physiology at three levels, 1) at the site of origin by targeting nociceptive neurons with pain modulating compounds including noxious stimuli and inflammatory mediators, 2) at the inhibitory GABAergic interneuron, and 3) at the ascending spinal level by targeting glutamatergic DPNs. These circuits will be integrated utilizing expertise in patterning neurons as well as integration with BioMEMs devices. This system provides scientists with a better understanding of ascending pain pathway physiology and enable clinicians to consider alternative indications for treating pain at peripheral and spinal levels. |
||||||||
1R21TR004333-01
Show Summary |
Discovery of Novel Openers of the Understudied Human Drug Target Kir6.1 | Preclinical and Translational Research in Pain Management | Discovery and Validation of Novel Targets for Safe and Effective Treatment of Pain | NCATS | NEW YORK UNIVERSITY SCHOOL OF MEDICINE | CARDOZO, TIMOTHY J | New York, NY | 2022 |
NOFO Title: Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed)
NOFO Number: TR22-011 Summary: Routine treatment of pain with prescription opioid medications may evolve into opioid use disorder, addiction, and potentially overdose. New, non-opioid molecular targets for pain are needed as a key element of responding to the opioid and overdose crisis. Ion channels are molecular gateways that convert electrical signals into physiological responses, and many have been implicated in transmitting pain signals. The ion channel Kir6.1/KCNJ8 has been linked to the control of postoperative and cancer pain. Studies in animal models show that low levels of this ion channel are evident after an injury. This research will identify compounds that can open the Kir6.1/KCNJ8 channel as potential treatment strategy for pain. |
||||||||
3-UH3-AT010739-02
Show Summary |
Pragmatic Trial of Acupuncture for Chronic Low Back Pain in Older Adults | Clinical Research in Pain Management | Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing (PRISM) | NCCIH | KAISER FOUNDATION RESEARCH INSTITUTE | SHERMAN, KAREN J (contact); DEBAR, LYNN L | Oakland, CA | 2021 |
NOFO Title: HEAL Initiative: Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements to Support Strategies to Increase Participant Diversity, Inclusion and Engagement in Clinical Studies
NOFO Number: NOT-NS-21-025 |
||||||||
1R61AT012283-01
Show Summary |
Development and Identification of Magnetic Resonance, Electrophysiological, and Fiber-Optic Imaging Biomarkers of Myofascial Pain | Clinical Research in Pain Management | Discovery and Validation of Biomarkers, Endpoints, and Signatures for Pain Conditions | NCCIH | WASHINGTON UNIVERSITY | HU, SONG (contact); WANG, YONG | St. Louis, MO | 2022 |
NOFO Title: HEAL Initiative: Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management
NOFO Number: RFA-AT-22-003 Summary: Pain in muscles and surrounding connective tissue (myofascial pain) is a significant health concern affecting hundreds of millions of Americans. There is no objective way to identify and measure myofascial pain. This project will address this unmet challenge by developing a robust approach to identify imaging biomarker(s) that can distinguish different states of myofascial pain. The research will then examine the ability of identified biomarker(s) to predict patient responses to a myofascial pain treatment in a randomized controlled clinical trial. |
||||||||
1R61AT012282-01
Show Summary |
Development and Validation of a Multimodal Ultrasound-Based Biomarker for Myofascial Pain | Clinical Research in Pain Management | Discovery and Validation of Biomarkers, Endpoints, and Signatures for Pain Conditions | NCCIH | UNIVERSITY OF PITTSBURGH AT PITTSBURGH | WASAN, AJAY D (contact); KIM, KANG ; PU, JIANTAO | Pittsburgh, PA | 2022 |
NOFO Title: HEAL Initiative: Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management
NOFO Number: RFA-AT-22-003 Summary: Pain in the muscles and surrounding connective tissues (myofascial pain) can affect many regions of the body and is a key component of chronic low back pain. Patients with chronic low back pain have a range of musculoskeletal problems perpetuating their pain. There is a significant clinical need to identify the components of myofascial pain in people with chronic low back pain. Advances in ultrasound technology have allowed researchers to identify several differences in muscle and connective tissues related to myofascial pain. This project will develop and validate an ultrasound-based biomarker signature for myofascial pain in the low back. This research will also refine the biomarker signature using advanced machine learning approaches, toward future testing in in a randomized controlled clinical trial. |
||||||||
1U24AT010961-01
Show Summary |
HEAL Collaboratory Resource Coordinating Center (PRISM) | Clinical Research in Pain Management | Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing (PRISM) | NCCIH | DUKE UNIVERSITY | HERNANDEZ, ADRIAN (contact); CURTIS, LESLEY H; WEINFURT, KEVIN P | Durham, NC | 2019 |
NOFO Title: HEAL Initiative: Limited Competition: Resource Coordinating Center for Pragmatic and Implementation Studies for the Management of Pain (PRISM) to Reduce Opioid Prescribing (U24 Clinical Trial Not Allowed)
NOFO Number: RFA-AT-19-011 Summary: Improved pain management and reduction of opioid use could greatly benefit from improved pragmatic clinical trials (PCTs). The PRISM Resource Coordinating Center (CC), as part of the NIH Health Care Systems Research Collaboratory, will support up to nine more embedded PCTs that address pain management and the opioid crisis. Since 2012, the CC has nurtured 15 Demonstration Projects by providing leadership, resources, tools, training, and coordination of diverse elements. The CC will work collaboratively with each PRISM Demonstration Project team supported through the HEAL Initiative, including their partnering health care systems, to develop, test, and implement the projects while providing technical, design, and coordination support. The CC will also develop and refine technical and policy guidelines and best practices for the effective conduct of pain-related research studies in partnership with health care systems and disseminate best strategies for successful embedded PCTs. |
||||||||
1R61AT012185-01
Show Summary |
MRI-Based Quantitative Characterization of Impaired Myofascial Interface Properties in Myofascial Pain Syndrome | Clinical Research in Pain Management | Discovery and Validation of Biomarkers, Endpoints, and Signatures for Pain Conditions | NCCIH | MAYO CLINIC ROCHESTER | YIN, ZIYING (contact); BAUER, BRENT A | Rochester, MN | 2022 |
NOFO Title: HEAL Initiative: Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management
NOFO Number: RFA-AT-22-003 Summary: Pain in the muscles and surrounding connective tissue (myofascial pain) is a significant health concern affecting hundreds of millions of Americans. Understanding and managing myofascial pain has been limited due to a lack of tools to help clinicians diagnose and treat this disorder. While past efforts to understand myofascial pain have focused on impairments in how connective tissues connect to other tissues in the body, this project will use a new imaging technique to study myofascial tissue physical properties, including how they move in the body and their structural stiffness. This research will identify an imaging biomarker to be used in a randomized controlled clinical trial to predict patient responses to a myofascial pain treatment. |
||||||||
1R61AT012279-01
Show Summary |
Quantifying and Treating Myofascial Dysfunction in Post Stroke Shoulder Pain | Clinical Research in Pain Management | Discovery and Validation of Biomarkers, Endpoints, and Signatures for Pain Conditions | NCCIH | JOHNS HOPKINS UNIVERSITY | RAGHAVAN, PREETI | Baltimore, MD | 2022 |
NOFO Title: HEAL Initiative: Developing Quantitative Imaging and Other Relevant Biomarkers of Myofascial Tissues for Clinical Pain Management
NOFO Number: RFA-AT-22-003 Summary: Shoulder pain occurs in many patients who are recovering from a stroke. In addition to impairments in the ability to move, persistent shoulder pain contributes to depression, and often reduces quality of life. Although the cause of post-stroke shoulder pain is complex and not completely understood, it is thought to arise in part to damage of muscles and surrounding connective tissues (myofascial tissues) in the shoulder. This project will use advanced medical imaging techniques to create biomarkers of that can reliably identify myofascial tissues. The research will then test the ability of these biomarkers to monitor, and ultimately predict treatment responses in patients with post-stroke shoulder pain in the context of a randomized controlled clinical trial. |